8-K
filed June 2, 2026, 5:26 PM ET
CIK 0001460602
other material
confidence high
sentiment neutral
materiality 0.70
Orgenesis shareholders approve 10x increase in authorized shares to 150M and convertible loan deal
Orgenesis Inc.
- Shareholders approved amendment to increase authorized common shares from 14,583,333 to 150,000,000.
- Vote: 5,153,345 for, 61,005 against, 1,201,381 abstentions on the amendment.
- Approved Convertible Loan Agreement with Theracell Laboratories IKE and Alpha Prosperity Fund SPC for potential share issuance.
- Ratified appointment of Kesselman & Kesselman (PwC) as auditor for FY 2025; votes: 6,400,038 for, 14,552 against.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Orgenesis Inc.: Increased authorized shares of common stock from 14,583,333 to 150,000,000 (effective 2026-06-02).
- Change
- charter amendment
- Effective
- 2026-06-02
Exact text from the filing
the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Charter”), to increase the total number of authorized shares of the Company’s common stock from 14,583,333 to 150,000,000. On June 2, 2026, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Orgenesis Inc. shareholders approved Ratification of appointment of Kesselman & Kesselman C.P.A.s (member firm of PricewaterhouseCoopers) as independent registered public accounting firm for fiscal year ending December 31, 2025 at the 2026-05-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 3. Ratification of Auditors The approval of the ratification of the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2025: For Against Abstain 6,400,038 14,552 1,141
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Orgenesis Inc. shareholders approved Amendment to Articles of Incorporation to increase authorized shares of common stock from 14,583,333 to 150,000,000 at the 2026-05-27 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 1. Amendment to Articles of Incorporation to Increase Authorized Shares of Common Stock The approval of a proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 14,583,333 to 150,000,000: For Against Abstain 5,153,345 61,005 1,201,381
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Orgenesis Inc. shareholders approved Share Issuance Proposal - approval of Convertible Loan Agreement and potential issuance of shares at the 2026-05-27 meeting.
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 2. Share Issuance Proposal The approval of the Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P, and the potential issuance of shares of common stock of Orgenesis Inc. pursuant thereto: For Against Abstain 5,172,526 27,026 1,201,280
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.